Tracking Inflammation in CAR-T Therapy: The Emerging Role of Serum Amyloid A (SAA).

Cancers (Basel) · 2025 · PMC12523542 · PMID 41097712

Europe PMC DOI

hedged sentence

0.4980

closest p · 10.0× alpha

0.4980

boldest claim

The sentences

did not reach statistical significancep = 0.498not close (p > 0.1)

At baseline, SAA seemed lower in patients with lower disease bulk before CAR-T (responders to bridging therapy) compared to those with active disease after bridging, but this difference did not reach statistical significance (49.4 vs. 41.3 mg/L, p = 0.498; Mann–Whitney U test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.